Algorithm of treatment of glucocorticoid induced osteoporosis – search for criteria – editorial

Česká verzia

Authors: J. Štěpán
Authors place of work: Revmatologický ústav Praha a 1. lékařská fakulta UK Praha, přednosta prof. MUDr. Karel Pavelka, DrSc.
Published in the journal: Vnitř Lék 2009; 55(5): 448-454
Category: Editorials

Summary

Epidemiological data indicate twofold increase of low impact fractures (spine, hip, ribs, distal forearm, and shoulder) in patients on glucocorticoid treatment compared with untreated subjects. These risks are mainly independent of BMD and prevalent fracture. Early direct inhibitory effect of glucocorticoid on bone formation and promotion of apoptosis of bone cells are thought to be the major mechanism of glucocorticoid‑induced osteoporosis (GIO). Despite differences in pathogenesis of postmenopausal osteoporosis, GIO, and other types of osteoporosis, the algorithm of treatment of GIO should be based on the assessment of the individual absolute risk of fracture (FRAX) according to the WHO recommendations. Glucocorticoid‑induced bone loss should be prevented, and if present, should be treated. Considering long‑term character of GIO, the bone anabolic therapy should be used at absolute risk of hip fracture of ≥ 3%.

Key words:
BMD – fracture – glucocorticoid – treatment – osteoporosis

Zdroje

1. Kanis JA, Stevenson M, McCloskey EV et al. Glucocorticoid‑induced osteoporosis: a systematic review and cost‑utility analysis. Health Technol Assess 2007; 11: iii–iv, ix–xi, 1–231.

2. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid‑induced osteoporosis: a meta‑analysis. Osteoporos Int 2002; 13: 777–787.

3. Kanis JA, Johansson H, Oden A et al. A meta‑analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893–899.

4. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54: 49–52.

5. Naganathan V, Jones G, Nash P et al. Vertebral fracture risk with long‑term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 2000; 160: 2917–2922.

6. McKenzie R, Reynolds JC, O’Fallon Aet al. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol 2000; 27:2222–2226.

7. Lian KC, Lang TF, Keyak JH et al. Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women. Osteoporos Int 2005; 16: 642–650.

8. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1–129.

9. NIH Consensus Development Panel on Osteoporosis prevention, diagnosis, and therapy, March 7–29, 2000: highlights of the conference. South Med J 2001; 94: 569–573.

10. Assessment of osteoporosis at the primary health care level. Report of a WHO Study Group. In: Kanis JA (ed). University of Sheffield Medical School. UK: Sheffield 2007.

11. Saag KG. Prevention of glucocorticoid‑induced osteoporosis. South Med J 2004; 97: 555–558.

12. Štěpán J. Účinnost antiresorpční léčby postmenopauzální osteoporózy. Vnitř Lék 2007; 53: 293–299.

13. Štěpán J. Glukokortikoidy indukovaná osteoporóza: nové možnosti prevence a léčby. Interní Med 2008; 10: 323–326.

14. Dempster DW. Bone histomorphometry in glucocorticoid‑induced osteoporosis. J Bone Miner Res 1989; 4: 137–141.

15. Dalle Carbonare L, Arlot ME, Chavassieux PM et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid‑induced and postmenopausal osteoporosis. J Bone Miner Res 2001; 16: 97–103.

16. Bijlsma JW, Van Everdingen AA, Huisman M et al. Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann N Y Acad Sci 2002; 966: 82–90.

17. Dennison E, Hindmarsh P, Fall C et al. Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab 1999; 84: 3058–3063.

18. Cooper MS, Walker EA, Bland R et al. Expression and functional consequences of 11beta‑hydroxysteroid dehydrogenase activity in human bone. Bone 2000; 27: 375–381.

19. O’Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835–1841.

20. Štěpán J. Laboratorní diagnostika kostního metabolismu In: Zima T (ed). Laboratorní diagnostika. 2. vyd. Praha: Galén 2007: 229–269.

21. Růžičková O, Bayer M, Pavelka K et al. Doporučení pro prevenci a léčbu glukokortikoidy indukované osteoporózy u pacientů s revmatickým onemocněním (Společné stanovisko České revmatologické společnosti a Společnosti pro metabolická onemocnění skeletu). Čes Revmatol 2004; 12: 163–174.

22. van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383–1389.

23. Mann V, Huber C, Kogianni G et al. The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007; 40: 674–684.

24. Crawford BA, Liu PY, Kean MT et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long‑term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88: 3167–3176.

25. Štěpán J, Weiss V, Marek J et al. Spontánní úprava kortikosteroidní osteopenie po úspěšné chirurgické léčbě Cushingova syndromu. Průřezová studie. Čas Lék Čes 1997; 136: 464–467.

26. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid‑induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292–299.

27. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‑induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006–1013.

28. Lems WF, Lodder MC, Lips P et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low‑dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006; 17: 716–723.

29. Patlas N, Golomb G, Yaffe P et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999; 60: 68–73.

30. Franchimont N, Canalis E. Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev 2003; 2: 224–228.

31. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995; 136: 3632–3638.

32. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid‑induced osteoporosis. N Engl J Med 2007; 357: 2028–2039.

33. Tosteson AN, Melton LJ 3rd, Dawson--Hughes B et al. Cost‑effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008; 19: 437–447.

34. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid‑induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309–2318.